Calendar note: The request describes the report as “tomorrow (2026-08-04),” but today is Tuesday, August 4, 2026. This is therefore a day-of preview for Gilead’s 2Q26 earnings release and conference call.
Gilead enters 2Q26 with a fundamentally constructive operating setup: HIV is growing, Yeztugo is ramping faster than initially planned, Trodelvy and Livdelzi are adding diversification, and several consequential regulatory and pipeline events are approaching.
The complication is accounting. Investors should expect the quarter to be dominated by the previously flagged upfront acquired-I PR&D charges associated with the Arcellx, Ouro Medicines, and Tubulis transactions. Gilead guided to full-year GAAP EPS of $(3.25) to $(2.85) and non-GAAP EPS of $(1.05) to $(0.65), including the acquisitions’ upfront charges and financing costs. Management previously characterized those items as roughly $9.50 per share of impact. Thus, the market should focus less on reported EPS and more on:
The long-acting HIV PrEP launch is the most important near-term source of upside. In 1Q26, Yeztugo generated $166 million of sales, up 72% sequentially, and Gilead raised its full-year Yeztugo outlook to approximately $1 billion, from approximately $800 million previously.
Management’s commentary since earnings has remained upbeat: coverage, provider onboarding, buy-and-bill adoption, patient awareness, and early return-dose behavior have all tracked at or ahead of internal expectations. The key question for 2Q is whether the first-quarter launch strength was repeatable—and whether management can provide greater confidence around persistence and new-to-PrEP adoption.
What investors should watch - Quarterly Yeztugo sales versus the run-rate needed to support the $1 billion full-year target. - Mix of switches from oral PrEP versus patients new to PrEP. - Evidence that uptake is broadening beyond established high-PrEP markets. - Persistence/return-dose commentary, which is especially important for a twice-yearly injectable product.
A material beat in Yeztugo would strengthen the case that Gilead’s PrEP franchise can expand rather than merely cannibalize Descovy. A slowdown, or cautious commentary on persistence, would likely be the most consequential commercial disappointment.
In 1Q26, HIV sales grew 10% year over year to $5.0 billion, led by Biktarvy, Descovy, and Yeztugo. Biktarvy grew 7% to $3.4 billion, while Descovy grew 38% to $807 million. Management subsequently raised its 2026 HIV-growth outlook to approximately 8%, despite an estimated roughly 2% policy-related headwind.
For 2Q, investors will be looking for normalization after first-quarter inventory drawdown and seasonal effects. The core debate is not whether Biktarvy remains the standard of care—it does—but whether Gilead can use new long-acting and novel regimen options to retain more patients who would otherwise switch away from the franchise.
The next near-term catalyst is the FDA decision on BIC/LEN, Gilead’s once-daily bictegravir/lenacapavir regimen, with a PDUFA date of August 27, 2026. Management has positioned the product as a way to address patients on complex multi-tablet regimens and compete more effectively for switch patients.
Key read-throughs - Biktarvy: demand, pricing, market share, and channel inventory. - Descovy: whether PrEP demand remains strong despite Yeztugo’s expansion. - Yeztugo: whether early launch performance supports further confidence in the annual target. - BIC/LEN: launch-readiness, access expectations, and initial revenue expectations following a potential late-August approval.
Trodelvy delivered $402 million in 1Q26 sales, up 37% year over year, aided by demand growth, favorable inventory dynamics, and pricing. The strategic importance of the asset is increasing as Gilead awaits potential regulatory decisions in first-line metastatic triple-negative breast cancer.
Management has emphasized that Trodelvy already has NCCN Category 1 recommendations in first-line metastatic TNBC settings, ahead of potential FDA action later in 2026. The earnings call should help investors assess whether the product is already seeing pull-through from clinical enthusiasm and guideline support before a formal label expansion.
What to monitor - Underlying demand growth adjusted for inventory. - U.S. versus ex-U.S. contribution. - Management’s framing of competitive dynamics in TNBC. - Timing and confidence around first-line regulatory decisions. - Updates on the EVOKE-03 NSCLC and ASCENT-GYN endometrial-cancer programs, both expected in the second half.
Trodelvy is becoming increasingly important to the thesis because it is one of Gilead’s few sizable near-term oncology growth drivers ahead of the expected 2027 commercialization contribution from anito-cel.
Gilead’s legacy cell-therapy franchise remains under pressure. In 1Q26, cell-therapy sales fell 12% year over year to $407 million: Yescarta declined 14% and Tecartus declined 4%. Competitive pressure is ongoing in both in-class and out-of-class settings.
The offset is anito-cel, Gilead’s BCMA CAR-T candidate for relapsed/refractory multiple myeloma. FDA action is expected on December 23, 2026, and management expects commercial revenue to begin in early 2027, assuming approval. Gilead sees the fourth-line-plus opportunity as a roughly $3.5 billion market and has emphasized manufacturing readiness, broad treatment-center coverage, and anito-cel’s potential efficacy/safety differentiation.
The key issue is timing: 2Q results are unlikely to solve the current cell-therapy decline, but a credible launch plan for anito-cel can support confidence in a 2027 inflection.
Livdelzi sales were $133 million in 1Q26, more than tripling year over year. The launch has achieved more than 50% share of the U.S. second-line PBC market, according to management’s first-quarter commentary.
Since then, Gilead has said the Phase III IDEAL study generated efficacy data that could support use in earlier lines and potentially more than double the addressable patient population. Investors should look for more detail on the path to a label update, physician adoption, and the durability of Livdelzi’s market-share gains after the initial switching opportunity.
Gilead’s May guidance called for:
| 2026 guidance metric | Current range / outlook |
|---|---|
| Product sales | $30.0B–$30.4B |
| Product sales ex-Veklury | $29.4B–$29.8B |
| Veklury sales | ~$600M |
| HIV sales growth | ~8% |
| Yeztugo sales | ~$1.0B |
| GAAP EPS | $(3.25)–$(2.85) |
| Non-GAAP EPS | $(1.05)–$(0.65) |
The EPS outlook is not a clean reflection of the base business because it incorporates the acquisition-related IPR&D and financing impacts. On an underlying basis—excluding these transaction costs—management indicated that its prior operating outlook was broadly intact, with normalized non-GAAP EPS effectively remaining in the $8.45–$8.85 range.
A sales-guidance increase would be a clear positive, particularly if driven by Yeztugo and broader HIV strength rather than price or inventory. Maintaining guidance would likely be acceptable if management reiterates confidence in the Yeztugo ramp and explains that the second half contains the larger contribution from pending launches and label expansions.
The principal downside setup would be: - a Yeztugo trajectory that no longer clearly supports $1 billion, - a weaker-than-expected Biktarvy or Descovy trend, - Trodelvy sales that suggest deceleration after a strong 1Q, - or increased policy/pricing pressure that challenges the 8% HIV-growth outlook.
Gilead’s value proposition extends well beyond the quarter. The company has several events that can alter medium-term earnings power:
| Catalyst | Expected timing | Why it matters |
|---|---|---|
| BIC/LEN FDA decision | August 27, 2026 | New HIV switch-market option; reinforces franchise retention |
| ISLEND-1 / ISLEND-2 weekly oral HIV data | Positive topline reported; fuller disclosure expected | Potential first once-weekly oral treatment regimen |
| Trodelvy 1L mTNBC regulatory decisions | 2H26 | Could substantially expand the commercial opportunity |
| EVOKE-03 and ASCENT-GYN updates | 2H26 | Determines breadth of Trodelvy’s oncology expansion |
| Livdelzi IDEAL follow-up / regulatory strategy | 2H26 | Potential earlier-line PBC expansion |
| Anito-cel FDA decision | December 23, 2026 | Foundation for a 2027 cell-therapy growth inflection |
| Annual lenacapavir PrEP program | Potential 2028 launch target | Extends leadership in long-acting HIV prevention |
Gilead has deliberately deployed capital to add longer-duration growth assets. The Arcellx, Ouro, and Tubulis transactions are strategically coherent—respectively bolstering CAR-T, autoimmune/inflammation, and next-generation ADC capabilities—but they make 2Q accounting unusually noisy.
The near-term investor question is whether Gilead can absorb the investment while preserving its operating model. Management has argued that the expense increase in 2026–27 should be manageable, with room in R&D as several large legacy Phase III programs wind down. Its stated capital-allocation order remains investment in the business, selective M&A, a growing dividend, and opportunistic repurchases.
The recent share-price setup is relatively subdued: GILD closed at $131.18 on August 3, below its early-July high of $136.36, a decline of about 3.8%. That leaves room for a positive reaction if the company demonstrates that launch momentum and base-business growth are offsetting the near-term accounting burden from acquisitions.
The bull case into 2Q26: Gilead confirms that Yeztugo is tracking toward—or above—a $1 billion first full-year sales opportunity, HIV growth remains broad based, Trodelvy maintains strong demand ahead of first-line expansion, and management preserves or raises product-sales guidance. In that scenario, the market can look through acquisition-related EPS noise and focus on a strengthening 2027–28 growth profile.
The bear case: Yeztugo’s ramp moderates, Biktarvy/Descovy growth softens, Trodelvy’s 1Q strength proves inventory-assisted, or policy and pricing headwinds become more visible. Given the expected IPR&D-related earnings distortion, the market may have little tolerance for even modest operational shortfalls.
Most important metric: Yeztugo sales and forward commentary.
Most important financial framing: product sales excluding Veklury and normalized profitability—not reported GAAP EPS.
Most important strategic question: whether Gilead can convert its HIV leadership and newly acquired pipeline assets into durable growth before anito-cel and broader oncology/inflammation contributions arrive in 2027 and beyond.